Alphaform AG / Key word(s): Final Results
09.03.2012 11:25
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
AD HOC PUBLICATION pursuant to § 15 of the German Securities Trading Act
Alphaform vastly improves revenues and EBITDA, according to provisional
figures - Return still clearly negative due to book value depreciation at
Medimet
Feldkirchen, 9 March 2012 - Alphaform AG - a specialist in additive
manufacturing and one of the leading companies in the area of orthopaedic
implants and instruments - experienced strong growth in the financial year
2011. According to provisional figures, consolidated revenues increased by
28% to EUR 26.4 million. In the financial year 2010, they had totalled EUR
20.7 million. In the process, revenues grew markedly both in the
Prototyping & Additive Manufacturing business area and in Medical
Technology. EBITDA rose to EUR 1.0 million, following EUR 0.8 million in
the previous year. This is an increase of 25%. Net profit remained negative
at EUR -1.5 million (previous year EUR -1.4 million). This is partly due to
extraordinary book value depreciation of EUR 1.0 million at the subsidiary
Medimet GmbH.
Irrespective of this, the strategic repositioning introduced in the spring
of 2008 by expanding the business into the area of Medical Technology has
proved correct. This business area now generates approximately 40% of
consolidated revenues. However, in 2011, earnings in the Medical Technology
division suffered under high pricing pressure and, due to a strong growth,
under a disproportionateupturn in costs. Thus, in this division, the
operating business margin remained below expectations. Therefore, in the
second half of 2011 in particular, Alphaform concentrated on reducing costs
in the Medical Technology division. The management expects that the
measures that have been introduced and already implemented will have a
positive impact on earnings in 2012.
In the traditional area of prototype making with additive manufacturing
techniques (prototyping), Alphaform benefited considerably from a general
upturn. Revenuesthat had been lost as a result of the economic crisis and
a heavy decline of the Formula-1-Business had now vastly grown again. In
2011, incoming orders for prototyping received by Alphaform - adjusted for
Formula 1 - again reached the 2008 level. Operating earnings also developed
in a very pleasing manner in this division as a result of the cost
reduction measures performed during the crisis.
Forecast
In the financial year 2012, Alphaform will concentrate on further improving
Group earnings. In the process, the particular objective is to raise the
results of operations of the Medical Technology division to the customary
level in this segment which, in 2011, were unsatisfactory and weighed down
the Group as a whole. The Group has strengthened capacities in additive
manufacturing in the past few months in order to meet the logistical
requirements and do justice to the rise in output, the Group has
strengthened capacities in additive manufacturing. Alphaform anticipates
that the measures that have been introduced and already carried out in
Medical Technology will have a positive impact as well as the development
in the Prototyping & Additive Manufacturing division will remain positive.
Thus, Alphaform is expecting net income on Group level in 2012.
Contact:
Dr. Gordon Guth
CFO
ALPHAFORM AG
KapellenstraÃe 10
85622 Feldkirchen
Tel.: +49 89 905002 83
Fax: +49 89 9050021083
mailto:gguth@alphaform.de
Internet: www.alphaform.de
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
About Alphaform
Alphaform AG, headquartered in Feldkirchen near Munich, is a contract
manufacturer for complex components and products produced in smaller
batches, founded in 1996. The company is one of the Eruoprean market
leaders in rapid manufacturing and rapid prototyping. The company has a
leading position throughout Europe in the manufacture of orthopaedic
implants and instruments.
The core competence of Alphaform lies in the provision of comprehensive
application expertise with regard to processes and materials for the rapid
production of complex prototypes, tools, single components and small series
of plastics and metals. The focus of the company's work lies in orthopaedic
and medical technology as well as automotive.
About rapid manufacturing
Rapid manufacturing is automatic shift manufacturing of plastic and metal
parts, directly from CAD files and without casting moulds or press moulds.
Also known as direct manufacturing, 3D printing or e-manufacturing, rapid
manufacturing is seen globally as a growth field. Fore some years, these
manufacturing methods have enabled rapid tooling and rapid prototyping.
09.03.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Alphaform AG
KapellenstraÃe 10
85622 Feldkirchen
Germany
Phone: +49 (0)89 905002 - 0
Fax: +49 (0)89 905002 - 90
E-mail: ir@alphaform.de
Internet: www.alphaform.de
ISIN: DE0005487953
WKN: 548795
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: Alphaform AG: Alphaform vastly improves revenues and EBITDA, according to provisional figures - Return still clearly negative due to book value depreciation ad Medimet
| Source: EQS Group AG